# ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

> **NCT05018702** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 32 (estimated)

## Conditions studied

- HER2-positive, Metastatic Breast Cancer

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT05018702
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-14
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05018702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05018702, "ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05018702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*